Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
FineHeart Raises €83Million to Advance Implantable Medical Devices
FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.
Alessa Therapeutics Secures FDA Fast Track for Enolen
Alessa Therapeutics , a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Enolen, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.
Johnson & Johnson Reaches Deal to Expand Access, Lower Drug Costs
Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs.
Aurora Therapeutics Launches Personalized Gene Editing Platform
Aurora Therapeutics announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale.
Bruker Secures $500 Million MRI Superconductor Orders
The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets.
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
Revvity, Inc. announced a collaboration with Eli Lilly and Company that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals Xynthetica offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.
Novotech Appoints Anand Tharmaratnam as New CEO
Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer.
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.
INTENT Biologics Receives FDA Fast Track Designation for PEP Biologic
INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PEP Biologic for the treatment of diabetic foot ulcers (DFU) under IND 019567.
Viking Therapeutics Names Neil Aubuchon Chief Commercial Officer
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine diseases, announced the appointment of Neil Aubuchon as Chief Commercial Officer. Aubuchon brings more than 20 years of experience in the biopharmaceutical industry, with leadership roles across global commercial and marketing organizations and a strong background in cardiometabolic therapies.
Inova Health Partners with Notable for AI and Digital Strategy
Notable, a leading healthcare artificial intelligence platform designed to improve workforce productivity, announced a strategic partnership with Inova Health, a nonprofit healthcare provider in Northern Virginia serving more than four million patient visits each year. Inova will use Notable’s AI Platform to reduce administrative burden, address staffing challenges, and support a system-wide digital transformation initiative across its health system.
SpliceBio Appoints Don Munoz as Chief Financial Officer
SpliceBio, a clinical-stage company developing genetic medicines through protein splicing to treat diseases caused by mutations in large genes, announced that Don Munoz has joined the company as Chief Financial Officer. Based in Boston, Munoz is an experienced biotechnology finance executive with extensive expertise in financial strategy, corporate development, and operations, supported by a strong background in healthcare investment banking.
Orthopedic Care Partners Welcomes Rob Scoskie as Chief Development Officer
Orthopedic Care Partners has appointed Rob Scoskie as Chief Development Officer, strengthening the organization’s focus on strategic growth, market expansion, and long-term value creation. Scoskie brings over 25 years of healthcare leadership experience, including roles with physician-led networks, integrated health systems, and private equity-backed organizations. In his new role, he will oversee development strategy, including market growth, partnerships, and acquisitions, working closely with physician leaders and the executive team to guide OCP through its next phase of expansion
To share your insights, please write to us at sudipto@intentamplify.com
